Company
Dogma Biotech
Advancing central nervous system therapeutics through reprogrammable glycosylation
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
Claim, correct or request removal
Record updated 28 September 2026
About
Our platform decodes the uncharted space of glycomics, deciphering how subtle glycan variations define whether a protein reaches its target, crosses the blood–brain barrier, or becomes invisible to the immune system.
Funding snapshot
- Total raised
- $100KSum of rounds, as of 2026-09-18Source (opens in a new tab)
- Latest round
- Grant, $100K2025-07-11
Funding rounds
- Grant
- $100K2025-07-11, Company stated
Loading relationship preview